DDInter1642 DDInter299
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Carfilzomib {u} (Compound) binds {v} (Gene) PSMB8
Carfilzomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Carfilzomib {u} (Compound) causes {v} (Side Effect) Headache
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Carfilzomib (Compound) resembles Ritonavir (Compound)
Carfilzomib (Compound) binds PSMB8 (Gene)
Carfilzomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Carfilzomib (Compound) causes Headache (Side Effect)
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab